As a result, various IL-2 immunocytokines, which consist of IL-2 fused to antibodies targeting different tumor or TME antigens, have been developed and evaluated in tumor mouse models, yielding encouraging results [93,94,95,96,97,98,99,100,101,102,103]. This evidence concerns the gene IL2 and neoplasm.